PATHOPHYSIOLOGY OF HYPERTENSION: Edited by Nancy J. BrownTargeting angiotensinogen with RNA-based therapeuticsRen, Liweia,b; Colafella, Katrina M. Mirabitoc; Bovée, Dominique M.a; Uijl, Estrellitaa; Danser, A.H. JanaAuthor Information aDepartment of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands bAstraZeneca-Shenzhen University Joint Institute of Nephrology, Department of Physiology, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China cCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Australia Correspondence to A.H. Jan Danser, PhD, Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Room EE1418b, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands. Tel: +31 10 7043540; fax: +31 10 7044733; e-mail: email@example.com Current Opinion in Nephrology and Hypertension: March 2020 - Volume 29 - Issue 2 - p 180-189 doi: 10.1097/MNH.0000000000000586 Buy Metrics Abstract Purpose of review To summarize all available data on targeting angiotensinogen with RNA-based therapeutics as a new tool to combat cardiovascular diseases. Recent findings Liver-targeted, stable antisense oligonucleotides and small interfering RNA targeting angiotensinogen are now available, and may allow treatment with at most a few injections per year, thereby improving adherence. Promising results have been obtained in hypertensive animal models, as well as in rodent models of atherosclerosis, polycystic kidney disease and pulmonary fibrosis. The next step will be to evaluate the optimal degree of suppression, synergy with existing renin–angiotensin–aldosterone system blockers, and to determine harmful effects of suppressing angiotensinogen in the context of common comorbidities, such as heart failure and chronic kidney disease. Summary Targeting angiotensinogen with RNA-based therapeutics is a promising new tool to treat hypertension and diseases beyond. Their long-lasting effects are particularly exciting, and if translated to a clinical application of at most a few administrations per year, may help to eliminate nonadherence. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.